



NEW PRODUCT LAUNCH

Valeo Pharma Inc. is pleased to announce the launch of ONSTRYV (safinamide tablets).

ONSTRYV is indicated as an add-on therapy to a regimen that includes levodopa for the treatment of the signs and symptoms of idiopathic Parkinson's disease (PD) in patients experiencing "off" episodes while on a stable dose of levodopa.¹

ONSTRYV is available in 50 mg and 100mg tablets and treatment with safinamide should be started with a dose of 50 mg once per day, administered orally. After two weeks the dose may be increased to 100 mg once per day based on individual clinical need and tolerability.¹

For more information on the efficacy, safety and tolerability of safinamide tablets please contact your Valeo Pharma representative at 1-855-694-0151 (Toll-free) or via email at info@valeopharma.com.

Full prescribing information can be found at www.valeopharma.com/onstryv-eng-pristine-01fe2019.pdf

¹ Onstryv Canadian product monograph

Under License from Zambon S.p.A.

Valeo Pharma Inc. is the exclusive licensee and distributor of Onstryv® in Canada.

Onstryv is a registered trademark of Zambon S.p.A.



VALEO PHARMA®

16667, boul. Hymus
Kirkland, Quebec, H9H-4R9